AnalystsArthur HeArthur He's Stock Forecasts
AnalystsArthur He
Sectors:
Industries:
Analyst Ranking
Top 3%
#153 out of 5323 analysts
Average Return
+43.29%
Win Rate
61%59 out of 96
Risk vs Reward
Poor
Good
Arthur He's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Nektar TherapeuticsNKTR | +475.26% | $12.23 | $70.36 | 2025-03-13 - 2026-03-12 | Buy |
Nektar TherapeuticsNKTR | +424.01% | $13.06 | $68.42 | 2025-02-25 - 2026-02-24 | Buy |
Poseida Therapeutics IncPSTX | +335.27% | $2.16 | $9.38 | 2024-04-22 - 2024-11-26 | Buy |
Poseida Therapeutics IncPSTX | +294.12% | $2.38 | $9.38 | 2024-10-30 - 2024-11-26 | Buy |
Poseida Therapeutics IncPSTX | +269.29% | $2.54 | $9.38 | 2024-10-17 - 2024-11-26 | Buy |
Arthur He Analyst Color
Get additional color on Arthur He's coverage of popular stocks
Arthur He's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Satellos Bioscience IncMSLE | 3 | Buy | $18.00 | +105.71% | Maintains | 7 days ago |
Vera Therapeutics IncVERA | 5 | Buy | $125.00 | +194.12% | Maintains | 8 days ago |
Prime Medicine IncPRME | 8 | Buy | $8.00 | +129.23% | Upgrades | 17 days ago |
Solid Biosciences IncSLDB | 12 | Buy | $25.00 | +159.88% | Maintains | a month ago |
Jade Biosciences IncJBIO | 4 | Buy | $55.00 | +151.60% | Maintains | a month ago |
Nektar TherapeuticsNKTR | 7 | Buy | $185.00 | +170.86% | Maintains | 3 months ago |
Adagene IncADAG | 11 | Buy | $7.00 | +90.74% | Maintains | a year ago |
Lava Therapeutics NvLVTX | 11 | Hold | $1.24 | -28.74% | Maintains | a year ago |
Aurinia Pharmaceuticals IncAUPH | 1 | Buy | $17.00 | +5.59% | Assumes | a year ago |
Adaptimmune Therapeutics PLCADAPY | 6 | Buy | $3.00 | N/A | Maintains | a year ago |
Poseida Therapeutics IncPSTX | 17 | Hold | $9.00 | N/A | Downgrades | 2 years ago |
Hookipa Pharma IncHOOK | 6 | Buy | $60.00 | N/A | Maintains | 2 years ago |
Calliditas Therapeutics AbCALT | 4 | Hold | $39.00 | N/A | Downgrades | 2 years ago |
Bioatla IncBCAB | 6 | Buy | $350.00 | N/A | Reiterates | 2 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.